Security key
M74240108
NeuroSense Therapeutics Ltd. - ORDINARY SHARES (NRSN)
CUSIP: M74240108
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / ORDINARY SHARES
- Total 13F shares
- 379,710
- Total 13F value
- $286,654
- Share change
- +33,576
- SEC-reported price per share
- $0.76
- Number of holders
- 13
- Value change
- +$24,591
- Number of buys
- 4
- Number of sells
- 6
Report period
Q1 2026
Institutions
13
Top holders
10
NRSN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
NeuroSense Therapeutics Ltd. SEC filings
NeuroSense Therapeutics Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M74240108
Recent filing periods:
Ownership snapshot
Top reported holders of NRSN - NeuroSense Therapeutics Ltd. - ORDINARY SHARES (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Hagit Binder
Disclosed value leader
Hagit Binder
Comparable rows
0/15
Latest evidence
26 Mar 2026
3/4/5
13F
Highest disclosed value: $401,268
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Hagit Binder has the largest disclosed position value at $401.3K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Hagit Binder's linked filing trail.
Disclosed position value
Top 5
Hagit Binder
$401.3K
Ferenc Tracik
$376.6K
Niva Russek-Blum
$359.9K
Mark Leuchtenberger
$108.2K
Cary J. Claiborne
$87.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Hagit Binder |
3/4/5
General Manager
|
—
mixed-class rows
|
$401,268
531,806 shares
mixed-class rows
|
— | 26 Mar 2026 |
| Ferenc Tracik |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$376,649
428,011 shares
|
— | 18 Mar 2026 |
| Niva Russek-Blum |
3/4/5
Chief Technology Officer
|
—
mixed-class rows
|
$359,855
477,953 shares
mixed-class rows
|
— | 26 Mar 2026 |
| Mark Leuchtenberger |
3/4/5
Director
|
—
class O/S missing
|
$108,196
122,951 shares
|
— | 18 Mar 2026 |
| Cary J. Claiborne |
3/4/5
Director
|
—
class O/S missing
|
$87,910
99,898 shares
|
— | 18 Mar 2026 |
| Christine A. Pellizzari |
3/4/5
Director
|
—
class O/S missing
|
$87,910
99,898 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
13
Shares
379,710
Rows available
13
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
13
Q1 2026 holders
13
Holder diff
0
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend